RNA Therapy
RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Indication (Cancer, Cardiovascular, Genetic Disorders), End User - Global Forecast 2024-2030
360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the rna therapy market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[199 Pages Report] The RNA Therapy Market size was estimated at USD 2.18 billion in 2023 and expected to reach USD 2.60 billion in 2024, at a CAGR 22.38% to reach USD 8.98 billion by 2030.

RNA therapy includes developing and commercializing therapeutic approaches that utilize ribonucleic acid (RNA) molecules to target specific genetic sequences and cellular mechanisms. These therapies treat various diseases and conditions by replacing faulty genes, silencing harmful gene expressions, or modulating cellular functions by targeting RNA molecules. Increasing investments in biotechnology startups, growing collaborations between academia and industry players, and an expanding portfolio of potential therapeutic targets for unmet medical needs drive the need for RNA therapies. Favorable regulatory policies for orphan drug designation and fast-track approvals have accelerated the clinical development of several RNA-based therapies. Delivery challenges associated with instability and rapid degradation of RNA molecules in vivo hampers market growth. Ongoing advancements by pharmaceutical companies to leverage cutting-edge technologies into novel RNA treatments for rare diseases with limited treatment options are expected to create opportunities for market growth.

Regional Insights

The RNA therapy market in the Americas is supported by a developed healthcare sector and supportive government programs, resulting in considerable commercialization of cutting-edge RNA therapies in the United States and Canada and the evolving pharmaceutical industry in South American countries. The governments in the Americas encourage technological advancements and research activities to provide a better healthcare system to people that contribute to overall economic growth and public welfare. The governments in the Asia-Pacific region's emerging and developed economies, such as Japan, India, China, and South Korea, encourage research and development of RNA therapies. Europe has significantly adopted RNA therapies owing to the rapid commercialization and acceptability of new devices and technologies, enabling healthcare professionals to use RNA therapies. On the other hand, the surging geriatric population in Europe is expected to increase the indication of several infectious and chronic disorders. As per the Population Reference Bureau (PRB), Russia, Germany, Italy, France, the UK, Spain, Turkey, Ukraine, Poland, Nigeria, and Iran are some countries that have a significant percentage of the population aged over 65 years. The rising indication of Europe's aging population and disorders necessitates efficient RNA therapies.

RNA Therapy Market
To learn more about this report, request a free PDF copy
Market Dynamics

The market dynamics represent an ever-changing landscape of the RNA Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Growing understanding of the role of RNA in disease pathology
    • Heightened demand for personalized medicine
    • Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
  • Market Restraints
    • High costs associated with RNA therapy development processes
  • Market Opportunities
    • Increased investments by governments and private organizations in research and development activities
    • Pipelined clinical trials of RNA-based therapeutics
  • Market Challenges
    • Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines
Market Segmentation Analysis
  • Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.

    Enabled technology drives the advancement in RNA therapy as it provides the tools necessary for precisely manipulating and delivering RNA molecules to target cells. This technology silences specific genes by introducing small interfering RNAs (siRNAs) into cells. Enabling technologies facilitate the development and application of enabled technologies by providing improved RNA molecule design, synthesis, modification, and delivery methods. Enabled technologies such as RNA interference (RNAi), Antisense Oligonucleotides (ASOs), and messenger Ribonucleic Acid (mRNA) therapeutics offer different approaches to modulating gene expression depending on the targeted disease mechanism.

  • Indication: Widespread applications of RNA therapy in genetic and cancer diseases.

    RNA therapy is crucial in cancer treatment by targeting specific oncogenes or tumor suppressor genes. These therapies help to regulate gene expression, which is often disrupted in cancerous cells. Need-based preference for RNA therapy in cancer includes personalized treatments tailored to the patient's genetic makeup. RNA therapy has potential applications for treating cardiovascular diseases such as heart failure and hypertension by modulating the expression of disease-related genes. Patients with severe or rare cardiovascular conditions may benefit from these targeted therapies as they offer fewer side effects and better efficacy compared to conventional treatments. RNA therapy can be used to treat genetic disorders caused by mutations or deficiencies in single genes. This need-based preference focuses on patients with rare, life-threatening genetic diseases with limited treatment options. By modulating host immune responses or directly targeting pathogens, RNA therapy can help combat viral and bacterial infections such as COVID-19, hepatitis B, and tuberculosis. Preference exists for patients suffering from drug-resistant infections or requiring rapid response treatments during outbreaks. RNA therapy provides new treatment options for chronic kidney diseases such as polycystic kidney disease and diabetic nephropathy by targeting specific genes involved in renal function and fibrosis. RNA therapy has the potential to treat metabolic disorders, including obesity, non-alcoholic steatohepatitis (NASH), and type 2 diabetes by regulating key genes involved in glucose and lipid metabolism. In addition to cancer vaccines, RNA therapy is used to develop personalized immunotherapies for various tumor types by encoding patient-specific tumor antigens. This need-based preference targets patients with aggressive or metastatic cancers that do not respond well to standard treatments. RNA therapy helps to treat retinal diseases caused by genetic mutations, such as Leber's congenital amaurosis and age-related macular degeneration, by delivering functional copies of the affected genes directly into retinal cells.

  • End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.

    In academic research, RNA therapy is primarily utilized for understanding gene function and regulation. Researchers employ various RNA therapeutic approaches such as small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), microRNAs (miRNAs), and messenger RNA (mRNA) therapeutics. RNA-based diagnostics focuses on detecting disease-specific biomarkers through targeted sequencing or gene expression profiling. These diagnostic methods offer increased sensitivity compared to traditional DNA-based techniques. RNA-targeted drug discovery and development involve identifying novel therapeutic targets, designing selective RNA-binding small molecules or oligonucleotides, and developing innovative delivery systems to overcome cellular barriers.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the RNA Therapy Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the RNA Therapy Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the RNA Therapy Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the RNA Therapy Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the RNA Therapy Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the RNA Therapy Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the RNA Therapy Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the RNA Therapy Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the RNA Therapy Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the RNA Therapy Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the RNA Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the RNA Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing

    ADARx Pharmaceuticals, a clinical-stage biotechnology firm specializing in next-generation RNA therapeutics, has completed a Series C funding round, raising USD 200 million. The funding enabled ADARx Pharmaceuticals to advance ADARx's clinical programs, including ADX-324 and ADX-038. The former represents a pioneering approach for treating hereditary angioedema (HAE), a rare genetic disorder characterized by painful, rapid swelling attacks that can be life-threatening. Additionally, the funding is estimated to facilitate the progress of an innovative pipeline comprising mRNA silencing or editing candidates to treat various diseases. [Published On: 2023-08-09]

  • ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million

    ReNAgade Therapeutics announced the funding of USD 300 million to revolutionize RNA therapeutics. This considerable funding underscores confidence in ReNAgade's potential to address vital limitations currently faced by RNA therapies while paving the way for pioneering treatment options and improved patient care. ReNAgade Therapeutics' entrance into the market with such robust financial backing highlights the continuing growth of next-generation healthcare solutions. [Published On: 2023-05-23]

  • Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

    Esperovax, an innovative biotechnology firm specializing in oral mRNA therapies, has entered into a strategic collaboration with Ginkgo Bioworks to advance the development of circular RNAs (circRNAs) for a wide range of therapeutic applications. The initial focus of the collaborative efforts between Esperovax and Ginkgo Bioworks enabled the designing and production of circRNAs carrying precise payloads that specifically target colorectal cancer. This pioneering methodology is intended to promote apoptosis or programmed cell death solely within malignant cells, leaving healthy tissue untouched. By leveraging Ginkgo Bioworks' cutting-edge platform for cellular engineering and Esperovax's expertise in oral mRNA biologics, the partnership seeks to bring forth novel circRNA-based treatment options that could revolutionize the field of oncology. [Published On: 2023-01-05]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the RNA Therapy Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Deep Genomics, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Ionis Pharmaceuticals, Inc., Laronde, MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, Novartis AG, Novo Nordisk A/S, Nutcracker Therapeutics, Inc., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Triplet Therapeutics, Inc..

RNA Therapy Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Enabled Technologies
      • Inhibition
      • Labeling
      • Linear amplification
      • Microarrays
      • Purification
      • qRT-PCR
    • Enabling Technologies
      • RNA Antisense Technologies
        • MicroRNA
        • Small interfering RNA
      • RNA Interference Technologies
  • Indication
    • Cancer
    • Cardiovascular
    • Genetic Disorders
    • Infectious Diseases
    • Kidney Diseases
    • Metabolic Disorders
    • Oncology
    • Retinal Diseases
  • End User
    • Academic Research
    • Diagnostics
    • Drug Discovery & Development

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the RNA Therapy Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. RNA Therapy Market, by Technology
  7. RNA Therapy Market, by Indication
  8. RNA Therapy Market, by End User
  9. Americas RNA Therapy Market
  10. Asia-Pacific RNA Therapy Market
  11. Europe, Middle East & Africa RNA Therapy Market
  12. Competitive Landscape
  13. Competitive Portfolio
  14. List of Figures [Total: 22]
  15. List of Tables [Total: 566]
  16. List of Companies Mentioned [Total: 28]
The Promising Future of RNA Therapy
October 9, 2023
BLOG
The Promising Future of RNA Therapy
RNA therapy has become an emerging player in the medical field, particularly in treating genetic disorders and deficiencies. It can potentially revolutionize how diseases are treated, as it provides a personalized approach to medicine. This blog post discusses the significance of mRNA medicine in treating genetic diseases, its scope in treating deficiencies, and the future of RNA therapy.

mRNA, or messenger RNA, is crucial in decoding DNA information and producing proteins that facilitate most biological functions. That is why using mRNA therapy to treat genetic disorders, such as cystic fibrosis, is an innovative approach. Cystic fibrosis is a genetic disease that causes serious damage to the lungs, digestive system, and other organs. Traditional treatments could only provide symptomatic relief. However, mRNA therapy can target the root cause of the disease by repairing or replacing the malfunctioning genes responsible for cystic fibrosis.

Apart from genetic disorders, RNA therapy also shows promise in treating deficiencies. This therapy delivers synthetic RNA molecules to certain cells that translate the RNA into proteins. RNA therapy also provides a personalized approach to medicine, as RNA sequences can be tailored to target specific cells or tissues, making it a versatile treatment modality.

Another exciting feature of RNA therapy is its potential to treat cancer. Researchers are investigating different RNA sequences to target specific cancer cells, inhibit their growth and spread, or cause their destruction. Given that cancer is a leading cause of death worldwide, RNA therapy offers potential hope for cancer patients, which could pave the way for novel treatments that are more effective and less toxic than traditional chemotherapy.

RNA therapy is a promising field of medicine that can revolutionize how we treat diseases. It provides a personalized approach to medicine, essential for diseases that cause genetic deficiencies or mutations. With the continuous breakthroughs in RNA therapy, there is hope for developing more efficient and personalized treatments that can provide long-lasting results. RNA therapy's future looks bright, and we can't wait to see how it will improve humankind's overall health and well-being.

Frequently Asked Questions
  1. How big is the RNA Therapy Market?
    Ans. The Global RNA Therapy Market size was estimated at USD 2.18 billion in 2023 and expected to reach USD 2.60 billion in 2024.
  2. What is the RNA Therapy Market growth?
    Ans. The Global RNA Therapy Market to grow USD 8.98 billion by 2030, at a CAGR of 22.38%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.